Sage Therapeutics, Inc. (SAGE): Price and Financial Metrics


Sage Therapeutics, Inc. (SAGE): $32.24

0.31 (+0.97%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SAGE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SAGE POWR Grades


  • Growth is the dimension where SAGE ranks best; there it ranks ahead of 34.02% of US stocks.
  • The strongest trend for SAGE is in Value, which has been heading down over the past 179 days.
  • SAGE ranks lowest in Stability; there it ranks in the 10th percentile.

SAGE Stock Summary

  • SAGE's price/sales ratio is 330.47; that's higher than the P/S ratio of 98.89% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.05 for Sage Therapeutics Inc; that's greater than it is for only 6.12% of US stocks.
  • Revenue growth over the past 12 months for Sage Therapeutics Inc comes in at -99.43%, a number that bests only 0.66% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Sage Therapeutics Inc are FREQ, BLUE, RETA, ACRS, and AKTS.
  • Visit SAGE's SEC page to see the company's official filings. To visit the company's web site, go to www.sagerx.com.

SAGE Valuation Summary

  • In comparison to the median Healthcare stock, SAGE's price/earnings ratio is 88.77% lower, now standing at 4.1.
  • SAGE's price/sales ratio has moved NA NA over the prior 87 months.
  • Over the past 87 months, SAGE's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for SAGE.

Stock Date P/S P/B P/E EV/EBIT
SAGE 2021-08-31 2.4 1.4 4.1 3.3
SAGE 2021-08-30 2.4 1.4 4.0 3.2
SAGE 2021-08-27 2.4 1.4 4.0 3.2
SAGE 2021-08-26 2.3 1.3 3.8 3.0
SAGE 2021-08-25 2.3 1.3 3.8 3.1
SAGE 2021-08-24 2.3 1.3 3.8 3.1

SAGE Growth Metrics

    Its 3 year net income to common stockholders growth rate is now at -326.83%.
  • Its year over year net cashflow from operations growth rate is now at 234.23%.
  • Its year over year net income to common stockholders growth rate is now at 198.99%.
SAGE's revenue has moved down $666,000 over the prior 15 months.

The table below shows SAGE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 6.308 -378.182 -457.892
2021-09-30 1,113.852 730.29 641.715
2021-06-30 1,114.051 708.1 666.151
2021-03-31 1,113.497 691.885 637.049
2020-12-31 1,114.2 664.28 606.073
2020-09-30 6.974 -463.417 -537.475

SAGE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SAGE has a Quality Grade of C, ranking ahead of 62.22% of graded US stocks.
  • SAGE's asset turnover comes in at 0.544 -- ranking 73rd of 681 Pharmaceutical Products stocks.
  • VTGN, SVRA, and SESN are the stocks whose asset turnover ratios are most correlated with SAGE.

The table below shows SAGE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.544 0.999 0.571
2021-06-30 0.637 0.999 0.746
2021-03-31 0.767 0.999 0.960
2020-12-31 0.954 0.999 1.092
2020-09-30 0.008 0.907 -0.813
2020-06-30 0.009 0.929 -0.814

SAGE Price Target

For more insight on analysts targets of SAGE, see our SAGE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $85.11 Average Broker Recommendation 1.66 (Moderate Buy)

SAGE Stock Price Chart Interactive Chart >

Price chart for SAGE

SAGE Price/Volume Stats

Current price $32.24 52-week high $79.45
Prev. close $31.93 52-week low $27.36
Day low $31.23 Volume 558,200
Day high $32.54 Avg. volume 650,944
50-day MA $33.24 Dividend yield N/A
200-day MA $39.24 Market Cap 1.90B

Sage Therapeutics, Inc. (SAGE) Company Bio


Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare central nervous system, or CNS, disorders. The company was founded in 2010 and is based in Cambridge, Massachusetts.


SAGE Latest News Stream


Event/Time News Detail
Loading, please wait...

SAGE Latest Social Stream


Loading social stream, please wait...

View Full SAGE Social Stream

Latest SAGE News From Around the Web

Below are the latest news stories about Sage Therapeutics Inc that investors may wish to consider to help them evaluate SAGE as an investment opportunity.

Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Highlights Pipeline and Business Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company fearlessly leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2021. “2021 was a data rich year marked by important advancements in multiple disease areas across all of our brain health franchises,” said Barry Greene, chief executive officer at Sage Therapeutics. “I’m excite

Business Wire | February 24, 2022

Sage Therapeutics'' (SAGE) CEO Barry Greene on Q4 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | February 24, 2022

Sage Therapeutics GAAP EPS of -$2.12 beats by $0.05, revenue of $1.6M misses by $0.17M

Sage Therapeutics press release (SAGE): Q4 GAAP EPS of -$2.12 beats by $0.05.Revenue of $1.6M (-99.9% Y/Y) misses by $0.17M.Ended 2021 with cash balance of $1.7 billion;…

Seeking Alpha | February 24, 2022

The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics

Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog.

Yahoo | February 24, 2022

Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Misses Revenue Estimates

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.85% and 8.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Read More 'SAGE' Stories Here

SAGE Price Returns

1-mo 2.28%
3-mo -11.36%
6-mo -17.14%
1-year -53.68%
3-year -81.26%
5-year -50.21%
YTD -24.21%
2021 -50.83%
2020 19.84%
2019 -24.64%
2018 -41.84%
2017 222.58%

Continue Researching SAGE

Here are a few links from around the web to help you further your research on Sage Therapeutics Inc's stock as an investment opportunity:

Sage Therapeutics Inc (SAGE) Stock Price | Nasdaq
Sage Therapeutics Inc (SAGE) Stock Quote, History and News - Yahoo Finance
Sage Therapeutics Inc (SAGE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7126 seconds.